Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report

Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report

ABSTRACT The mesenchymal‐epithelial transition factor (MET) Y1003 mutation, like MET ex14 skipping, is an oncogenic driver mutation that suppresses MET degradation. Herein, we report the case of a 63‐year‐old female patient with lung adenocarcinoma harboring the MET Y1003N mutation, who was treated...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Yukihiro Umeda, Satomi Kimura, Junya Kimura, Yoshiaki Imamura, Tamotsu Ishizuka
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: Wiley 2025-01-01
Seri Bilgileri:Thoracic Cancer
Konular:
adenocarcinoma of lungs
MET Y1003
mutation
tepotinib
tyrosine kinase inhibitors
Online Erişim:https://doi.org/10.1111/1759-7714.15508

Internet

https://doi.org/10.1111/1759-7714.15508

Benzer Materyaller